Since its establishment in 2012, Dibier Biotech has made it its mission to lead industry progress and promote industrial upgrading. Through continuous innovation and breakthroughs, it has developed an integrated solution centered around micro-scale parallel reactors, incorporating automated instruments for medium preparation, automatic inoculation, automatic sampling, and a smart data management cloud platform. This marks a crucial step from "High Throughput Screening" to "High Throughput Process Development (HTPD)", not only filling the domestic gap and breaking international monopolies but also impacting international brands in overseas markets.

    In addition to advanced hardware, the company's core business also encompasses the development of basic industrial software, leveraging cloud-based data monitoring and artificial intelligence and big data technologies to establish a digital intelligent manufacturing platform. Its products cover multiple industrial "six bases" fields and strategic emerging industries' key product and service guidance catalogues, addressing "weaknesses" and "gaps" in key areas of the industrial chain. The company has provided over 10,000 high-throughput, automated, miniature bioreactor research and development platforms to more than 100 universities and over 600 enterprise customers in emerging fields such as synthetic biology, gene and cell therapy, globally. This has strongly supported the rapid development of biomanufacturing fields such as synthetic biology, carbon neutrality, and biomedicine. The company has successively obtained honors such as Shanghai High-tech Enterprise and National-level Specialized, Fine, Unique, and Innovative Little Giant Enterprise, and boasts a Shanghai Academician Expert Workstation and a Shanghai Enterprise Technology Center.

     While pursuing self-improvement, Dibier Biotech actively promotes technological exchanges and cooperation across the upstream and downstream of the industry chain, both domestically and internationally. This includes promoting bioreactor data interfaces and biodata standardization, publishing the "Blue Book of Precision Fermentation Technology", hosting international forums on precision fermentation technology, participating in national key research and development projects related to intelligent reactors and data, and achieving a consensus within the industry to "co-create a data-driven biotechnology industry". In the future, we will continue to work together to decode the art of fermentation through data, restore the beauty of life through science, and make greater contributions to the further development of China's bioeconomy.

    Corporate website: https://www.parallel-bioreactor.com/